Cenix BioScience is a contract research organization focused on the discovery and pre-clinical development of novel therapeutics, specializing in advanced applications of RNA interference (RNAi) gene silencing combined with high content phenotyping in cultured cells in vitro and in animals in vivo.
Now in its 11th year, Cenix has built-up solid scientific and commercial track records, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields.
The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured human and rodent cells, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs.
As such, Cenix is a mature, reliable, and fully-proven industrial research partner, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none worldwide. …